Lucy Godley to Leukemia, Myeloid, Acute
This is a "connection" page, showing publications Lucy Godley has written about Leukemia, Myeloid, Acute.
Connection Strength
5.940
-
Germline mutations in MDS/AML predisposition disorders. Curr Opin Hematol. 2021 03 01; 28(2):86-93.
Score: 0.447
-
Hereditary Myelodysplastic Syndrome and Acute Myeloid Leukemia: Diagnosis, Questions, and Controversies. Curr Hematol Malig Rep. 2018 12; 13(6):426-434.
Score: 0.383
-
MBD4: guardian of the epigenetic galaxy. Blood. 2018 10 04; 132(14):1468-1469.
Score: 0.378
-
Identifying patients with genetic predisposition to acute myeloid leukemia. Best Pract Res Clin Haematol. 2018 12; 31(4):373-378.
Score: 0.378
-
Germline ETV6 mutations and predisposition to hematological malignancies. Int J Hematol. 2017 Aug; 106(2):189-195.
Score: 0.345
-
Inherited predisposition to acute myeloid leukemia. Semin Hematol. 2014 Oct; 51(4):306-21.
Score: 0.284
-
On the origin of leukemic species. Cell Stem Cell. 2014 Apr 03; 14(4):421-2.
Score: 0.277
-
Profiles in leukemia. N Engl J Med. 2012 Mar 22; 366(12):1152-3.
Score: 0.240
-
An integrated genomic approach to the assessment and treatment of acute myeloid leukemia. Semin Oncol. 2011 Apr; 38(2):215-24.
Score: 0.225
-
Therapy-related myeloid leukemia. Semin Oncol. 2008 Aug; 35(4):418-29.
Score: 0.187
-
Implications of FLT3 mutations in the therapy of acute myeloid leukemia. Rev Recent Clin Trials. 2007 May; 2(2):135-41.
Score: 0.171
-
Genetic risk classification for adults with AML receiving less-intensive therapies: the 2024 ELN recommendations. Blood. 2024 Nov 21; 144(21):2169-2173.
Score: 0.145
-
Insights into the Molecular Mechanisms of Genetic Predisposition to Hematopoietic Malignancies: The Importance of Gene-Environment Interactions. Cancer Discov. 2024 Mar 01; 14(3):396-405.
Score: 0.138
-
Clinical and molecular response of acute myeloid leukemia harboring non-canonical FLT3 N676K driver mutations to contemporary FLT3 inhibitors. Haematologica. 2023 08 01; 108(8):2234-2239.
Score: 0.132
-
(R)-2-Hydroxyglutarate Inhibits KDM5 Histone Lysine Demethylases to Drive Transformation in IDH-Mutant Cancers. Cancer Discov. 2023 06 02; 13(6):1478-1497.
Score: 0.131
-
Germ line DDX41 mutations define a unique subtype of myeloid neoplasms. Blood. 2023 02 02; 141(5):534-549.
Score: 0.128
-
Genomic profiling for clinical decision making in myeloid neoplasms and acute leukemia. Blood. 2022 11 24; 140(21):2228-2247.
Score: 0.126
-
Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022 09 22; 140(12):1345-1377.
Score: 0.125
-
The RUNX1 database (RUNX1db): establishment of an expert curated RUNX1 registry and genomics database as a public resource for familial platelet disorder with myeloid malignancy. Haematologica. 2021 11 01; 106(11):3004-3007.
Score: 0.117
-
RUNX1-mutated families show phenotype heterogeneity and a somatic mutation profile unique to germline predisposed AML. Blood Adv. 2020 03 24; 4(6):1131-1144.
Score: 0.105
-
A phase 1 study of azacitidine with high-dose cytarabine and mitoxantrone in high-risk acute myeloid leukemia. Blood Adv. 2020 02 25; 4(4):599-606.
Score: 0.104
-
Correct application of variant classification guidelines in germline RUNX1 mutated disorders to assist clinical diagnosis. Leuk Lymphoma. 2020 01; 61(1):246-247.
Score: 0.102
-
A phase I study of selinexor in combination with high-dose cytarabine and mitoxantrone for remission induction in patients with acute myeloid leukemia. J Hematol Oncol. 2018 01 05; 11(1):4.
Score: 0.090
-
Reduced-Intensity Allogeneic Transplant for Acute Myeloid Leukemia and Myelodysplastic Syndrome Using Combined CD34-Selected Haploidentical Graft and a Single Umbilical Cord Unit Compared with Matched Unrelated Donor Stem Cells in Older Adults. Biol Blood Marrow Transplant. 2018 05; 24(5):997-1004.
Score: 0.090
-
Therapy-related myeloid neoplasms: when genetics and environment collide. Nat Rev Cancer. 2017 08 24; 17(9):513-527.
Score: 0.088
-
Efficacy of single-agent decitabine in relapsed and refractory acute myeloid leukemia. Leuk Lymphoma. 2017 09; 58(9):1-7.
Score: 0.085
-
Novel germ line DDX41 mutations define families with a lower age of MDS/AML onset and lymphoid malignancies. Blood. 2016 Feb 25; 127(8):1017-23.
Score: 0.078
-
Fumarate and Succinate Regulate Expression of Hypoxia-inducible Genes via TET Enzymes. J Biol Chem. 2016 Feb 19; 291(8):4256-65.
Score: 0.078
-
Genomic analysis of germ line and somatic variants in familial myelodysplasia/acute myeloid leukemia. Blood. 2015 Nov 26; 126(22):2484-90.
Score: 0.077
-
Inherited and Somatic Defects in DDX41 in Myeloid Neoplasms. Cancer Cell. 2015 May 11; 27(5):658-70.
Score: 0.074
-
DNA hydroxymethylation profiling reveals that WT1 mutations result in loss of TET2 function in acute myeloid leukemia. Cell Rep. 2014 Dec 11; 9(5):1841-1855.
Score: 0.073
-
Familial myelodysplastic syndrome/acute leukemia syndromes: a review and utility for translational investigations. Ann N Y Acad Sci. 2014 Mar; 1310:111-8.
Score: 0.068
-
2-Hydroxyglutarate in IDH mutant acute myeloid leukemia: predicting patient responses, minimal residual disease and correlations with methylcytosine and hydroxymethylcytosine levels. Leuk Lymphoma. 2013 Feb; 54(2):408-10.
Score: 0.061
-
The histone code and treatments for acute myeloid leukemia. N Engl J Med. 2012 Mar 08; 366(10):960-1.
Score: 0.060
-
Gene mutations, epigenetic dysregulation, and personalized therapy in myeloid neoplasia: are we there yet? Semin Oncol. 2011 Apr; 38(2):196-214.
Score: 0.056
-
Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse. Blood. 2011 Mar 24; 117(12):3294-301.
Score: 0.056
-
Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell. 2010 Dec 14; 18(6):553-67.
Score: 0.055
-
A phase I biological study of MG98, an oligodeoxynucleotide antisense to DNA methyltransferase 1, in patients with high-risk myelodysplasia and acute myeloid leukemia. Clin Cancer Res. 2008 Apr 15; 14(8):2444-9.
Score: 0.046
-
Outcomes of patients with AML and MDS who relapse or progress after reduced intensity allogeneic hematopoietic cell transplantation. Bone Marrow Transplant. 2007 Dec; 40(11):1027-32.
Score: 0.044
-
Targeting the CD74 signaling axis suppresses inflammation and rescues defective hematopoiesis in RUNX1-familial platelet disorder. Sci Transl Med. 2025 Jan 08; 17(780):eadn9832.
Score: 0.037
-
TTID: A novel gene at 5q31 encoding a protein with titin-like features. Genomics. 1999 Sep 01; 60(2):226-33.
Score: 0.025
-
Increased DNA methylation of Dnmt3b targets impairs leukemogenesis. Blood. 2016 Mar 24; 127(12):1575-86.
Score: 0.020
-
Phase I-II study of clofarabine-melphalan-alemtuzumab conditioning for allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2012 Jun; 18(6):913-21.
Score: 0.015